Lessons from the Pandemic

What do you think is the greatest lesson learned from the COVID-19 pandemic, and what lasting impacts do you foresee over the next 5–10 years?

Dealing with a Crisis

How has your organization worked to become “crisis proof?”

Post-COVID-19 Supply Chain

How are you rethinking your supply chain and operational fitness in light of the COVID-19 pandemic?

Drug Pricing Solutions

What steps is your company taking to address drug pricing issues?

COVID-19

What is your perspective on how the pharma industry has responded to the COVID-19 pandemic? What lessons have been learned?

Roundtable Topics

Lessons from the Pandemic

Dealing with a Crisis

Post-COVID-19 Supply Chain

Drug Pricing Solutions

COVID-19

View all Roundtables

Over the past three decades, the pharmaceutical supply chain has grown more complex and international to meet policies focused on aggressively decreasing drug prices.

Andrew Badrot
CEO, C² PHARMA

The greatest lesson we have learned is that cumulative ability, expertise, and knowledge offer the best path forward in developing new drugs and therapies.

Anthony Fitzpatrick
Executive Vice President Operations, Vectura

Preparedness for risks such as anthrax and smallpox are important because the threat remains high, but we never expected that the first significant pandemic since the flu pandemic was going to be an extreme version of the common cold.

Sean Kirk
EVP, Manufacturing & Technical Operations, Emergent BioSolutions

To me, the greatest lesson learned from the COVID-19 pandemic is resilience: the CDMO industry has proven to be capable of outstanding resilience over the past months.

Jean Bléhaut
President of the Synthesis Solutions Business Unit, Novasep

First, the importance of our industry: both the ability of biopharmaceutical companies to directly address the challenges of COVID-19 and the fact that our sector has remained so strong in such turbulent times.

Ben Zeskind, Ph.D.
CEO, Immuneering

VIEW ALL ANSWERS

Because we’re a leading supplier for end-to-end bioprocessing products, our sector has been greatly impacted by COVID-19.

Amélie Boulais
Marketing Manager within the Vaccine Segment, Sartorius

Like every global organization, Catalent has crisis management plans in place for various scenarios. Surveillance and communication are key and help identify threats quickly to enable timely response.

Kay Schmidt
Senior Vice President, Technical Operations, Catalent

Obviously, the safety and well-being of trial participants and staff remains the top priority of any organization conducting clinical studies, but it is absolutely imperative that the quality and integrity of data from trials remains of the highest standard.

Nariné Baririan
PharmD, Clinical Pharmacology Expert, SGS

While the advent of the COVID-19 pandemic brought about a tumultuous period across industries, we demonstrated operational resilience and established ourselves as a “crisis-proof” organization.

Radek Špíšek, Ph.D.
Global CEO, Sotio

The key to overcoming any crisis is robust planning, eliminating single points of failure, adapting quickly, and building a culture of creative problem solving.

Dietrich Stephan, Ph.D.
CEO, Neubase Therapeutics

VIEW ALL ANSWERS

Alcami’s simplified, entirely U.S.-based supply chain is one of our core strengths. At every phase of the product life cycle, risks are inevitable; this is especially true as supply chain complexities increase due to COVID-19.

Yadira Salamander
Director of Engineering Services, Alcami

The COVID-19 pandemic has highlighted the critical role that procurement plays in managing the supply of goods and services, especially in times of crisis. Business continuity planning has been used to great effect and has reinforced the need to keep plans live and...

David Duff
VP Procurement, Vectura

At BASF Nutrition and Health, global, regional, country, and site crisis-management teams are meeting regularly to further monitor the outbreak of COVID-19 and recommend the necessary mitigation measures.

David Freidinger
Vice President of Pharma Solutions Business Management, BASF

The COVID-19 pandemic has provided many lessons and inspiration for improvement related to areas from people to processes and systems.

Brian Albright
Global Manufacturing and Supply Chain Leader, Pharma Solutions, DuPont Nutrition & Biosciences

The continuous optimization of operational fitness has always been an integral part of Rentschler Biopharma’s strategy. We have been closely monitoring and improving our processes, business continuity, and digital maturity, even before the outbreak of the COVID-19 ...

Wolfram Schulze
Vice President Information Systems, Organization, & Digital Transformation and Head of Infection Prevention Task Force, Rentschler Biopharma

VIEW ALL ANSWERS

Our biggest focus is in digitalization and investing across our business to enable a virtual world, which enables faster decision-making and more efficient solutions that can help address cost profiles throughout the industry.

Brian Albright
Global Manufacturing and Supply Chain Leader, Pharma Solutions, DuPont Nutrition & Biosciences

In acknowledgment of our essential role in the value stream of drug development and manufacturing, we continuously strive to excel at each discipline within our service portfolio.

Wolfram Schulze
Vice President Information Systems, Organization, & Digital Transformation and Head of Infection Prevention Task Force, Rentschler Biopharma

Although drug pricing is ultimately up to the pharmaceutical and biopharmaceutical companies, we are taking steps at PCI to simplify the supply chain to help drug companies realize more efficiencies.

Brad Payne
Chief Operating Officer, PCI Pharma Services

Although CDMO costs related to APIs and drug products often represent only a small percentage of the final drug price, Hovione invests continuously in technologies and processes to improve customer value.

Jean-Luc Herbeaux, Ph.D.
Chief Operations Officer, Hovione

In November 2019, BASF launched our Virtual Pharma Assistants, a suite of cutting-edge tools aimed at supporting the most critical elements of pharmaceutical manufacturing and catalyzing the process of formulation, qualification, and procurement of key ingredients ...

David Freidinger
Vice President of Pharma Solutions Business Management, BASF

VIEW ALL ANSWERS

There has been a massive global response to the COVID-19 pandemic. Many pharmaceutical companies have been making significant efforts to develop tests, treatments, and vaccines for COVID-19. They are leveraging and sharing their profound scientific knowledge. ...

Thierry Durand, Ph.D.
Managing Director, Minakem

It has been impressive to see how fast the industry responded to the outbreak. Once the genome of the virus was discovered, many set out to shut down the viral replication with many different approaches.

Christa Myer
Senior Associate / Senior Pharmaceutical Specialist, CRB USA

The COVID-19 pandemic has unveiled the complex landscape of the pharmaceutical industry, highlighting its strengths and weaknesses.

Marco Taglietti, M.D.
President & CEO, SCYNEXIS

The pharmaceutical and biopharmaceutical industries have responded promptly to the COVID-19 pandemic challenge by evaluating possible utilization of available drugs, speeding the clinical testing for the new application for drugs originally developed for diseases w...

Daria Donati, Ph.D.
Director, Business Development and Innovation, Cytiva

The pharmaceutical industry responded to the COVID-19 pandemic in a responsible manner and is fully supportive of efforts of various governmental agencies in responding quickly to the challenges this pandemic represents.

Madhu Shaik, Ph.D.
Executive Director of R&D & Technical Services, Alcami

VIEW ALL ANSWERS